Key result
MultiStem stromal stem cell therapy shows potential as a prophylaxis for acute GVHD.
Answers are grounded in this paper and cite their sources.
MultiStem merits evaluation as GVHD prophylaxis; leaves open its clinical role pending full efficacy and safety data.
Stromal stem cells are actively studied as a novel adjunct therapy after HSCT. Safety of mesenchymal stromal cells was shown in early phase clinical trials with benefit for engraftment and treatment of acute or steroid refractory GVHD (Lazarus 2005, LeBlanc 2008, Kebriaei 2009). Phase III trials have reported mixed outcomes for MSC therapy for acute or steroid refractory GVHD (Martin 2010, Prasad 2010). Multipotent adult progenitor cells (MultiStem®) is a stromal stem cell source with similar immune-modulatory activity as MSC and can be manufactured to clinical scale allowing all patients on an individual study to be treated with uniform allogeneic cell product from a universal donor.
No takes yet. Share an insight, caveat, or question.
Maziarz et al. (2011) studied Acute GVHD. Stromal Stem Cell Therapy (MultiStem®) was evaluated. Stromal stem cell therapy (MultiStem) is introduced as a potential prophylaxis for acute GVHD, but no quantitative results are provided in the abstract.
Synapse has enriched 10 related papers. Consider them for comparative context: